Top Suppliers Rapid Antigen Test Nasal Swab - KaiBiLi COVID-19 Antigen – saliva cup – Genesis
Top Suppliers Rapid Antigen Test Nasal Swab - KaiBiLi COVID-19 Antigen – saliva cup – Genesis Detail:
Introduction
The KaiBiLiTM COVID-19 Antigen Rapid Test Device is an in vitro diagnostic test based on the principle of immunochromatography for the qualitative detection of 2019 Novel Coronavirus nucleocapsid protein antigens in saliva. The detection is based on the antibodies which were developed specifically recognizing and reacting with the nucleoprotein of 2019 Novel Coronavirus. It is intended to aid in the rapid diagnosis of SARS-CoV-2 infection.
COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main symptoms including manifestations include fever, fatigue and dry cough, nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
Features & Benefits
The KaiBiLiTM COVID-19 Antigen Rapid Test is an immunochromatographic assay for the qualitative detection of 2019 Novel Coronavirus antigens. This assay is intended for rapid screening in laboratory. This test should be conducted by trained technician, wearing appropriate personal protective equipment (PPE). The COVID-19 Antigen Rapid Test has two letters on the surface of the test device indicating test line (T) and control line (C). Test line and control line in the result window are not visible before applying any samples. The control line is a reference line which indicates the test is performing properly. The control line must appear every time when the test is performed. If SARS-CoV-2 is present in the sample, the test line would appear. The highly selective antibodies to SARS-CoV-2 are used as capture and detector in the assay. These antibodies can detect SARS-CoV-2 antigens directly, with a high accuracy.
Detection
The qualitative detection of 2019 Novel Coronavirus nucleocapsid protein antigens in saliva.
Specimen
Saliva
Limit of Detection (LoD)
2019 Novel Coronavirus: 74.8 TCID50/mL
Accuracy
Positive Percent Agreement: 96.5%
Negative Percent Agreement:97.8%
Overall Percent Agreement: 97.2%
Time to Results
Read results at 15minutes and no more than 30 minutes.
Kit Storage Conditions
2~30°C.
Contents
|
Description |
Qty |
| COVID-19 antigen test devices |
20 |
| Saliva collectors (cup and lip) |
20 |
| Plastic pipettes |
20 |
| Extraction tubes (with 0.5mL extraction buffer) |
20 |
| Nozzles with filter |
20 |
| Tube Stand |
1 |
| Package Insert |
1 |
Ordering Information
|
Product |
Cat.No. |
Contents |
|
KaiBiLiTM COVID-19 Antigen |
P211140-C |
20 Tests |
Product detail pictures:
Related Product Guide:
"Sincerity, Innovation, Rigorousness, and Efficiency" is the persistent conception of our company for the long-term to develop together with customers for mutual reciprocity and mutual benefit for Top Suppliers Rapid Antigen Test Nasal Swab - KaiBiLi COVID-19 Antigen – saliva cup – Genesis , The product will supply to all over the world, such as: Paraguay, South Korea, Miami, With the enterprising spirit of" high efficiency, convenience, practicality and innovation", and in line with such serving guidance of "good quality but better price, " and "global credit", we've been striving to cooperate with the automobile parts companies all over the world to make a win-win partnership.
By Adela from United Arab Emirates - 2018.02.12 14:52
As an international trading company, we have numerous partners, but about your company, I just want to say, you are really good, wide range, good quality, reasonable prices, warm and thoughtful service, advanced technology and equipment and workers have professional training, feedback and product update is timely, in short, this is a very pleasant cooperation, and we look forward to the next cooperation!
By Rosemary from Rio de Janeiro - 2018.11.02 11:11
